Accéder au contenu
Merck
  • Effective treatment with combination of peripheral 5-hydroxytryptamine synthetic inhibitor and 5-hydroxytryptamine 2 receptor antagonist on glucocorticoid-induced whole-body insulin resistance with hyperglycemia.

Effective treatment with combination of peripheral 5-hydroxytryptamine synthetic inhibitor and 5-hydroxytryptamine 2 receptor antagonist on glucocorticoid-induced whole-body insulin resistance with hyperglycemia.

Journal of diabetes investigation (2016-11-03)
Shaoxin Ma, Tao Li, Keke Guo, Xin Li, Shanshan An, Shanshan Hou, Ru Chen, Bo Yang, Siyu Liu, Jihua Fu
RÉSUMÉ

Our previous study found that dexamethasone-induced insulin resistance (IR) was involved in 5-hydroxytryptamine (5-HT) synthesis and 5-hydroxytryptamine 2 receptor (5-HT Male rats were exposed to dexamethasone for 10 days, then treated with or without a 5-HT Dexamethasone-induced whole-body IR, with glucose intolerance, decreased insulin sensitivity, hyperglycemia, hyperinsulinemia and dyslipidemia, could be effectively abolished by sarpogrelate or/and carbidopa, whereas IR-related actions of dexamethasone in tissues were accompanied by increased 5-HT synthesis in the liver and visceral adipose, and upregulated 5-HT Inhibitions of both peripheral 5-HT synthesis and 5-HT

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Sarpogrelate hydrochloride, ≥98% (HPLC)